Kwality Pharmaceuticals Reports 46% YoY Revenue Surge in Q3 FY26, EBITDA Expands 67%

Kwality Pharmaceuticals Ltd. delivered a robust performance in Q3 and the first nine months of FY26, with consolidated revenue surging 46% YoY and EBITDA expanding 67% YoY. The growth was driven by strong demand for registered products in key international markets, strategic portfolio expansion, and deeper market penetration. The company initiated multiple Bioequivalence (BE) and clinical studies in the injectables and oral solid dosage segments to fortify the global product pipeline and accelerate regulatory approvals. KPL achieved several new product registrations in the quarter, solidifying its foothold in regulated and semi-regulated markets. The company is ideally positioned to seize emerging global opportunities and propel its next growth phase, with a target of %650 crore for FY27 and a 30% CAGR beyond FY27.